You are here: Industry Insights > Merck

News List

Lynparza, Bevacizumab Combination Approved for HRD-Positive Advanced Ovarian Cancer in the US americanpharmaceuticalreview
May 15, 2020
AstraZeneca and Merck announced that Lynparza (olaparib) in combination with bevacizumab has been approved in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Merck registers an increase of 16.7 per cent in net sales expresspharma
May 15, 2020
The COVID-19 crisis, which has meanwhile become a pandemic, only had a moderate impact in the first quarter of 2020, the company reported.
Skyhawk Therapeutics, Merck Expand RNA Alliance contractpharma
May 14, 2020
Aims to discover and develop novel small molecules that modulate RNA splicing for autoimmune and metabolic diseases.
Merck Granted US Patents for Foundational CRISPR-Cas9 Technology expresspharma
May 12, 2020
CRISPR technology is a core competency for Merck, which has 16 years’ experience with genome editing, spanning discovery to manufacturing.
Merck names Doina Ionescu as UK and Ireland general manager pharmatimes
May 07, 2020
Doina Ionescu has been named as the new managing director and general manager for the Merck Healthcare business in the UK and Republic of Ireland.
Merck accelerates readiness of bioprocessing facility of the future expresspharma
May 05, 2020
Bio4C software suite, a first-of-its-kind digital ecosystem, combines process control, analytics and plant-level automation.
Merck signs Covid-19 research alliance with ISB pharmaceutical-technology
April 30, 2020
Merck (MSD) has entered a research collaboration with the Institute for Systems Biology (ISB) to study molecular mechanisms of SARS-CoV-2 and Covid-19 infection.
Merck and Institute for Systems Biology Enter COVID-19 Collaboration contractpharma
April 29, 2020
To define molecular mechanisms of SARS-CoV-2 infection and identify potential prognostic biomarkers.
Merck announces US launch of ONTRUZANT, a biosimilar of Herceptin pharmaceutical-business-review
April 20, 2020
Merck announced the US launch of ONTRUZANT (trastuzumab-dttb), as a biosimilar of the reference biologic medicine Herceptin.
Samsung Bioepis, Merck Launch Trastuzumab Biosimilar americanpharmaceuticalreview
April 16, 2020
Samsung Bioepis announced ONTRUZANT® (trastuzumab-dttb), a biosimilar of the reference biologic medicine HERCEPTIN® (trastuzumab) for the treatment of ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page